Format Comparison
BPC-157 Oral vs Injection: Format Comparison
BPC-157 is one of the few peptides with demonstrated activity through both oral and injectable routes. The right format depends on whether the goal is gut-localised healing or systemic tissue repair.
Side-by-side comparison
| Attribute | BPC-157 (Oral) | BPC-157 (Subcutaneous) |
|---|---|---|
| Estimated bioavailability | 20 to 40 percent | 90 to 95 percent |
| Onset | 30 to 60 minutes | Minutes |
| Best suited for | Gut healing, gastric protection | Systemic tendon, muscle, joint repair |
| Storage | Room temperature capsules | Refrigeration after reconstitution |
| Clinical evidence base | Strong rodent gut models | Strong rodent musculoskeletal models |
Key differences
- ·Oral BPC-157 stays largely in the GI tract, ideal for gastric or intestinal targets
- ·Subcutaneous injection delivers ~90% bioavailability, better for tendons, ligaments, joints
- ·Oral administration typically 2x to 4x higher to offset first-pass losses
- ·Capsules need no reconstitution or cold chain, lowering compliance friction
Research summary
Sikiric et al. (2018) demonstrated oral BPC-157 retains stability through gastric acid and acts locally on GI mucosa. Systemic absorption is partial. For musculoskeletal targets the published literature uses subcutaneous or intraperitoneal routes almost exclusively, supporting injection for non-gut goals.